IDXX 最新10-Q变化
将 IDXX 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-04 与上一份 10-Q · 2026-05-05
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +53 | −16 | ~25 | 48 |
| 市场风险(第3项) | 文字有新增/删除 | +3 | −2 | ~5 | 7 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 0 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-04
Income from OperationsImpact from Foreign CurrencySegment and Other Income from OperationsIncome from OperationsImpact from Foreign CurrencySegment and Other Income from Operations
Three Months Ended June 30, 2026, Compared to Three Months Ended June 30, 2025
Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related and travel costs, as well as higher costs related to commercial expansion. General and administrative expense increased primarily due to higher personnel-related costs, and higher depreciation and amo…
Rapid assay revenue increased from higher realized prices, moderated by lower volumes primarily due to lower vector-borne disease testing, and a shift of customers’ pancreatic lipase testing to our Catalyst instrument platform.
The increase in reference laboratory diagnostic and consulting services revenue was due to higher testing volumes across all major regions and higher realized prices. Volume growth was supported by increased testing by existing customers, including sales of our expanded menu of tests, and by new cus…
相对上期删除的文字 · 来源:10-Q · 2026-05-05
Three Months Ended March 31, 2026, Compared to Three Months Ended March 31, 2025
Operating Expenses. Sales and marketing expense increased primarily due to higher personnel-related costs. General and administrative expense increased primarily due to a prior period reduction in accrued expense of approximately $9 million related to a litigation matter concluded in April 2025, hig…
Rapid assay revenue increased from higher realized prices, moderated by a decrease in volumes partially due to a shift of customers’ pancreatic lipase testing to our Catalyst instrument platform, as well as sector headwinds. The impact of changes in foreign currency exchange rates increased revenue …
The increase in reference laboratory diagnostic and consulting services revenue was due to higher testing volumes across regions and higher realized prices. The impact of changes in foreign currency exchange rates increased revenue growth by 2.5%.
The increase in CAG Diagnostics services and accessories revenue was primarily a result of a 12% growth in our installed base of premium instruments. The impact of changes in foreign currency exchange rates increased revenue growth by 3.6%.
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-08-04
For the Three Months Ended June 30,For the Six Months Ended June 30,
Operating profit increase (decrease), excluding hedge activity and exchange impacts on settlement of foreign currency denominated transactions$4,985 $5,490 $22,554 $(1,795)
Foreign currency transaction (gains) losses - comparable period in the prior year568 1,001 1,239 1,934
相对上期删除的文字 · 来源:10-Q · 2026-05-05
Operating profit increase (decrease), excluding hedge activity and exchange impacts on settlement of foreign currency denominated transactions$17,569 $(7,285)
Foreign currency transactions gains (losses) - current period(444)(671)
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议